Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sequential T-DM1 after anthracycline-based chemotherapy in early HER2-positive breast cancer
2010-019752-50Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2010
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab emtansine in breast cancer, sponsored by Roche. Primary endpoint: Cardiac event rate within 12 weeks after starting T-DM1. Started Jul 2010; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-019752-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019752-50.